AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Nuclidium raises over CHF100 million ($121M) to develop copper-based radiopharmaceuticals for cancer diagnosis and treatment.
Amount Raised
$121 Million
Round Type
Venture
BaselBiotechnologyHealth CareTherapeuticsDescription
Nuclidium, a Basel-based biotech startup founded in 2021, has raised over CHF100 million ($121 million) to advance its copper-based radiopharmaceuticals pipeline for diagnosing and treating cancers including metastatic prostate and breast cancer. The company's theranostic approach uses matched pairs of copper isotopes to both detect and treat cancer targets. CEO Leila Jaafar emphasizes that demonstrating clinical efficacy remains the primary challenge ahead. The US market for metastatic prostate cancer diagnosis and treatment alone is estimated to exceed $50 billion annually.
Fundz sees it the moment Nuclidium raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Nuclidium raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.